GEN-MKT-18-7897-A
Dec 1, 2015 | Blogs, Life Science Research, Proteomics | 0 comments
SWATH® Acquisition: On the Forefront of HIV-1 Research
World AIDS Day is held on the 1st December each year and is an opportunity for people worldwide to unite in the fight against HIV, show their support for people living with HIV, and to commemorate people who have died. World AIDS Day was the first ever global health day, held for the first time in 1988.
Source: http://www.worldaidsday.org/about
A research team at the University of Nebraska Medical Center (UNMC) is using SWATH Acquisition to advance a host-oriented antiviral strategy that targets the biomolecules required for viral replication.
Using SWATH for quantitative proteomics together with bioinformatic analyses to identify host proteins, the team quantified the expression of 3,608 proteins in uninfected and HIV-1-infected monocyte-derived microphages.
Of these, they found that 420 were significantly altered upon HIV-1 infection, and the findings highlighted a novel set of proteins and processes that are involved in the host response to HIV-1 infection.
Journal of Proteomics Research, 2014, April 4; Drs. P. Ciborowski, N. Haverland, H. Fox, University of Nebraska Medical Center or VIEW the webinar (May 2014) by Drs. Pawel Ciborowski and Nicole Haverland
In this informative presentation, you’ll learn:
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network